Form 4: Crinetics Pharmaceuticals Director Matthew K Fust Reports Stock and Option Transactions

Director Matthew K Fust reports acquisition of restricted stock units and stock options in Crinetics Pharmaceuticals.

Summary

• On June 7, 2024, Matthew K Fust, a director of Crinetics Pharmaceuticals, reported acquiring 3,400 shares of common stock and 12,500 stock options.
• The common stock was acquired through restricted stock units at a price of $0.
• These restricted stock units vest on the earlier of the first anniversary of the grant date or the next annual meeting, contingent upon continued service on the board.
• The stock options, with an exercise price of $44.71, also vest on the earlier of the first anniversary of the grant date or the next annual meeting, subject to continued board service.
• Following these transactions, Fust beneficially owns 21,936 shares of common stock and 12,500 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock and option grants to a director, indicating alignment of interests but not necessarily a strong positive or negative signal.

Positives

• The acquisition of stock and options by a director signals confidence in the company's future prospects.

Future Outlook

The vesting of the restricted stock units and stock options is contingent upon the director's continued service on the board, aligning their interests with the company's long-term success.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment due to the director's increased stake in the company.

Key Dates